New Data Reveals Actemra Is The First And Only Biologic Drug To Show Superiority Over Current Standard Of Care In Rheumatoid Arthritis

The novel rheumatoid arthritis drug Actemra (tocilizumab) has shown superiority over the current standard of care, methotrexate (MTX), by achieving a greater reduction of signs and symptoms (e.g. swollen and tender joints) at 6 months in patients suffering from rheumatoid arthritis.1 This positive outcome makes Actemra the first and only biologic therapy to have achieved superiority over MTX.



Furthermore, nearly three times as many patients treated with Actemra achieved disease remission (as defined by the globally recognised measure DAS28